1306844002: Allergy to cetuximab due to alpha-gal syndrome (finding)

• SNOMED CT Concept\Clinical finding (finding)\...
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to galactose-alpha-1,3 galactose\Allergy to cetuximab due to alpha-gal syndrome (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to cetuximab due to alpha-gal syndrome (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to galactose-alpha-1,3 galactose\Allergy to cetuximab due to alpha-gal syndrome (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to cetuximab due to alpha-gal syndrome (finding)
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to galactose-alpha-1,3 galactose\Allergy to cetuximab due to alpha-gal syndrome (finding)
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to cetuximab due to alpha-gal syndrome (finding)
• \Propensity to adverse reaction\Propensity to adverse reactions to drug\Allergy to drug\Allergy to cetuximab due to alpha-gal syndrome (finding)

Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Apr 2024. Module: SNOMED CT core

Descriptions:

Id	Description	Lang	Type	Status	Case?	Module
5316143018	Allergy to cetuximab due to alpha-gal syndrome (finding)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
5316144012	Allergy to cetuximab due to alpha-gal syndrome	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core

Expanded Value Set

Reference Sets

Description inactivation indicator reference set

GB English

US English

Back to Start